



# Update on AF Ablation: Canadian Evidence, Referrals, and Management

**FRIDAY, MAY 27, 2022**

12:10-12:30 pm EDT



## JASON ANDRADE

MD, FRCPC, FHRS  
Assistant Professor - Université de Montréal  
Clinical Faculty - University of British Columbia  
Vancouver, BC



## BRENNAN BALLANTYNE

MD, FRCPC  
Division of Cardiology, Libin Cardiovascular Institute  
University of Calgary  
Calgary, AB

Ablation for atrial fibrillation is usually considered only after pharmacological therapy. The delays between diagnosis and ablation can mean that established AF becomes more challenging to manage due to structural changes in the heart, increasing the risk of stroke and heart failure. Referring appropriate patients for ablation early in the process could lead to optimal outcomes, allowing patients to enjoy better health and improved quality of life, as well as to positively impact the health care system.

Join a conversation with Dr. Jason Andrade, PI of the EARLY-HF trial, and Dr. Brennan Ballantyne, Calgary's first EP/HF Fellow, to learn more about which patients are candidates for early ablation and some insights on the EARLY-HF study.

This Corridor Consult is available **LIVE** for the **VIRTUAL** audience and **ON-DEMAND** for all delegates after the congress

Visit [cardiovasupdate.ca](https://cardiovasupdate.ca) to register for the hybrid congress